Multi-drug delivery system using streptavidin-transforming growth factor-alpha chimeric protein

Area of Science:

• Biochemistry
• Molecular Biology
• Cell Biology

Background:

• Targeted delivery of molecules into specific cells is crucial for biological research and medical applications.
• Existing methods often require chemical linkage or genetic modification, posing limitations.

Purpose of the Study:

• To engineer a novel chimeric protein for efficient and non-invasive protein delivery into target cells.
• To assess the efficacy of the streptavidin-TGF-alpha (ST-TGF-alpha) chimeric protein in cellular uptake and functional delivery.

Main Methods:

• Construction and expression of a recombinant plasmid encoding streptavidin core and human transforming growth factor-alpha (TGF-alpha) in E. coli.
• Production of the ST-TGF-alpha chimeric protein.
• Assay of ST-TGF-alpha mediated delivery of biotinylated beta-galactosidase into A431 cells via epidermal growth factor receptor.
• Evaluation of the cytotoxic effect of ST-TGF-alpha complexed with biotinylated-glucose oxidase on A431 cells.

Main Results:

• The ST-TGF-alpha chimeric protein was successfully produced with both streptavidin and TGF-alpha activities.
• Efficient transfer (>99%) of biotinylated beta-galactosidase into A431 cells was achieved using ST-TGF-alpha.
• The ST-TGF-alpha complex induced significant cytotoxicity in A431 cells when combined with biotinylated-glucose oxidase.

Conclusions:

• The ST-TGF-alpha chimeric protein acts as a versatile molecular bridge for delivering various effector molecules into target cells.
• This approach eliminates the need for chemical conjugation or genetic engineering for protein delivery.
• ST-TGF-alpha offers a promising platform for targeted protein delivery in research and potential therapeutic strategies.